Drug Trial Radar · NCT07573449
How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male Participants
Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jan 22, 2024
Primary completion
Jan 22, 2025
Study completion Feb 27, 2025
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- May 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the absorption, metabolism and excretion of \[14C\]-JNT-517 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants following a single oral administration.
Conditions
- Healthy Volunteers
Interventions
[14C]-JNT-517Drug
Suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Radioactivity Recovery (fet1-t2) in Urine and FecesTime frame: Up to Day 9
- Relative Amounts Of Radioactivity Excreted in Urine and FecesTime frame: Up to Day 9
- Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-∞) of [14C]-JNT-517 And Its Metabolites in PlasmaTime frame: Up to Day 9
- Area Under The Concentration-Time Curve From Time Zero to The Time Of The Last Quantifiable Concentration (AUC0-tlast) of [14C]-JNT-517 And Its Metabolites in PlasmaTime frame: Up to Day 9
- Maximum Plasma Concentration (Cmax) of [14C]-JNT-517 And Its Metabolites in PlasmaTime frame: Up to Day 9
- Time to Reach Maximum (Peak) Observed Plasma Concentration (Tmax) of [14C]-JNT-517 And Its Metabolites in PlasmaTime frame: Up to Day 9
- Apparent Terminal Elimination Half-Life (t½) of [14C]-JNT-517 And Its Metabolites in PlasmaTime frame: Up to Day 9
- AUC₀-∞ of Total Radioactivity in Plasma And Whole BloodTime frame: Up to Day 9
- AUC₀-tlast of Total Radioactivity in Plasma And Whole BloodTime frame: Up to Day 9
- Cmax of Total Radioactivity in Plasma and Whole BloodTime frame: Up to Day 9
- Tmax of Total Radioactivity in Plasma and Whole BloodTime frame: Up to Day 9
- t½ of Total Radioactivity in Plasma and Whole BloodTime frame: Up to Day 9
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit Inc.
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.